- Home
- KC vs TARS Comparison
KC vs TARS Comparison
Compare KC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | TARS |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KC | TARS |
|---|---|---|
| Price | $12.29 | $72.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $18.00 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.4M | 720.9K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $30.93 | $56.43 |
| Revenue Next Year | $20.45 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $8.35 | $48.20 |
| 52 Week High | $18.52 | $85.25 |
Technical Indicators
Market Signals| Indicator | KC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 71.10 |
| Support Level | $10.94 | $60.95 |
| Resistance Level | $13.28 | $73.45 |
| Average True Range (ATR) | 0.39 | 3.16 |
| MACD | -0.02 | 0.99 |
| Stochastic Oscillator | 59.54 | 96.55 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.